HPV prevalence and type-distribution in cervical XXXX and premalignant lesions of the cervix: A population-based study from Northern Ireland.

@entity1 @entity5 @entity1083 @entity957 @entity1799 @entity1082 @entity420 @entity3146
INTRODUCTION: Assessment of @entity1082 ) prevalence and genotype distribution is important for monitoring the impact of prophylactic HPV vaccination. This study aimed to demonstrate the HPV genotypes predominating in pre-malignant and @entity5 in Northern Ireland (NI) before the vaccination campaign has effect. METHODS: Formalin fixed paraffin embedded tissue blocks from 2,303 @entity1 aged 16-93 years throughout NI were collated between April 2011 and February 2013. HPV DNA was amplified by PCR and HPV genotyping undertaken using the Roche   linear array detection kit. RESULTS: In total, 1,241 out of 1,830 eligible samples (68.0%) tested positive for HPV, with the majority of these [1,181/1,830 (64.5%)] having high-risk (HR) @entity1083 ; 37.4% were positive for @entity1799 (n   =   684) and 5.1% for HPV-18 (n   =   93). HPV type-specific prevalence was 48.1%, 65.9%, 81.3%, 92.2% and 64.3% among @entity3146 ( @entity3146 ) grades I-III, @entity957 ( @entity957 ) and @entity420 ( @entity420 ) cases, respectively. Most @entity957 cases (81.3%) had only one HPV genotype detected and almost a third (32.0%) of all cervical pathologies were HPV negative including 51.9% of @entity3146 I (n   =   283), 34.1% @entity3146 (n   =   145), 18.7% of @entity3146 (n   =   146), 7.8% of @entity957 (n   =   5) and 35.7% of @entity420 (n   =   5) cases. CONCLUSIONS: This study provides important baseline data for monitoring the effect of HPV vaccination in NI and for comparison with other UK regions. The coverage of other HR-HPV genotypes apart from 16 and 18, including HPV-45, 31, 39 and 52, and the potential for cross protection, should be considered when considering future polyvalent vaccines. This article is protected by copyright. All rights reserved.
